Key Investor Conferences Featuring PacBio
PacBio (NASDAQ: PACB), known for its cutting-edge sequencing solutions, has announced that its management team will actively participate in a series of important investor conferences over the coming weeks. These events represent an invaluable opportunity for investors to gain insights into the company’s innovative technologies and future direction.
Upcoming Conferences Overview
The company will be featured at several prestigious events. Notably, PacBio will attend the UBS Global Healthcare Conference on a Wednesday afternoon, where key industry topics and advancements will be discussed. Following that, they will be part of the Wolfe Research Healthcare Conference, set to occur on a Tuesday, offering further dialogue opportunities with stakeholders about industry developments and research capabilities.
Continuing this momentum, PacBio will also participate in the Stephens Annual Investment Conference, a venue that promises to spotlight the latest in healthcare advancements and their application in real-world scenarios. Lastly, the company has confirmed its presence at the Piper Sandler 36th Annual Healthcare Conference, where PacBio will elaborate on its strategic vision for the future of genomic sciences.
Accessing The Conferences
For those unable to attend in person, PacBio ensures that everyone can remain engaged with the discussions through live webcasts. Investors can access these webcasts on the company's investor relations page, and recordings will be accessible for an extended period post-event. This feature enables a wider audience to follow the developments and insights shared during these conferences.
About PacBio’s Innovations
PacBio stands at the forefront of life science technology, devoting its efforts to the advancement of sequencing solutions that assist researchers in tackling complex genetic challenges. The unique approach they employ combines two distinct yet complementary core technologies that prioritize precision and detail—HiFi long-read sequencing and SBB short-read sequencing.
As a leading contender in the field, their products are instrumental across a multitude of research disciplines such as genomics, oncology, and infectious disease studies. PacBio's comprehensive lineup not only provides solutions for human studies but extends to plant and animal research, highlighting its all-encompassing technology applications.
Commitment to Research Use
It is important to note that PacBio's products and technologies are exclusively for research use. They are not intended for use in diagnostic procedures, reaffirming the company's commitment to adhering to the regulatory standards of the scientific community.
Contacting PacBio
For inquiries regarding investor relations, Todd Friedman is the point of contact and can be reached at the provided email. Similarly, media representatives can direct their communication through the designated press contact email. Maintaining open lines of communication reinforces PacBio’s commitment to transparency with the public and its investors.
Frequently Asked Questions
1. What is the purpose of the investor conferences PacBio is attending?
The conferences serve as platforms for PacBio to engage with investors and discuss the latest advancements in genomic sequencing technology.
2. Where can I access the live webcasts of the conferences?
The live webcasts will be available on PacBio’s investor relations page during each conference.
3. What are the core technologies developed by PacBio?
PacBio's core technologies include HiFi long-read sequencing and SBB short-read sequencing, both emphasizing accuracy and quality.
4. Are PacBio's products meant for diagnostic use?
No, PacBio's products are designated for research use only and are not intended for diagnostic applications.
5. How can I contact PacBio for investor-related inquiries?
Investors can reach out to Todd Friedman via the email address provided for any inquiries related to investor relations.
